Abstract: A process for the preparation of a tertiary arylamine compound, comprising reacting an arylhalide, such as an arylbromide, and an arylamine in an alkylene glycol compound in the presence of a catalyst.

Abstract: Provided is a method of preparing an optically pure compound having formula 1 or its salts. The method includes: reacting (R)-2-(4-methoxy-3-aminosulfonyl-phenyl)-1 -methylethylamine or its salts with a compound selected from the group consisting of chloroacetic acid, bromoacetic acid, fluoroacetic acid, iodoacetic acid, ?-halogenoacetic acid anhydride, and ?-halogenoacetyl halide in the presence of a base or an acylating agent.

Abstract: Organosilicon compounds of the general formula I and/or II are produced by reacting silanes of the general formula III with alcohols of the general formula R?—OH, with elimination of R—OH, wherein R—OH may be continuously separated from the reaction mixture by distillation. The organosilicon compounds may be used in rubber mixtures. Compounds, such as rubbers, produced using such organosilicon compounds.

Abstract: Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the group consisting of N, O and S; L is any bivalent organic radical capable of linking each Q, such as C, CH, (CH2)l, or {(CH2)i-Y—(CH2)j}k, wherein Y is selected from the group consisting of CH2, an ether, a polyether, an amide, a polyamide, an ester, a sulfide, a urea, a thiourea, a guanidyl, a carbamoyl, a carbonate, a phosphate, a sulfate, a sulfoxide, an imine, a carbonyl, and a secondary amino group and wherein Y is optionally substituted by -X1-L?-X2-Z or -Z; R1-R6, independently of one another, are selected from the group consisting of H, —(CH2)p-D-Z, an alkyl, an alkenyl, an aryl, and an alkyl or alkyl ether optionally substituted by one or more of an alcohol, an aminoalcohol, an amine, an amide, an ether, a polyether, a polyamide, an ester, a mercaptan, an alkylthio, a urea, a thiourea, a guanidyl, or a carbamoyl group, and

Abstract: There is provided a regeneration process for converting oxazolidones such as hydroxypropyloxazolidone (HPOZD) to alkanolamines such as di-isopropanolamine (DIPA) and CO2. An amine stream containing HPOZD joins a stream that includes a caustic solution. The combined stream is passed to a tank where the caustic reacts with HPOZD to convert it to DIPA and CO2. The conversion of HPOZD to DIPA and CO2 requires a ratio of at least 2 moles of hydroxide for each mole of HPOZD in the solution. The conversion reaction is carried out in a reaction vessel at a temperature above 60° C. The reaction mixture is held in a feed tank for approximately 2 hours while being constantly mixed. After the reaction is completed, the mixture is allowed to settle which results in the virtually complete separation of the amine phase (containing DIPA, and water) from the caustic phase.

Abstract: A process for preparing an intermediate compound of formula (II) where n is an integer of from 3 to 14; R1 is haloC1-10alkyl, C1-10alkyl, C2-10alkenyl, C2-10cycloalkyl, carboxyC1-10alkyl, C1-10alkoxycarbonylC1-10alkyl, aryl (such as phenyl), aryl(C1-10)alkyl (such as phenyl(C1-10)alkyl) or di(C1-6alkyl)amino; and R2 is a halo group; the process comprising halogenation of a compound of formula (III) where n and R1 are as defined above. Novel compounds are also described and claimed.

Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.

Abstract: A class of N-cyclohexylaminocarbonyl benzenesulfonamide derivatives are agonists or partial agonists or antagonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.

Abstract: The present invention is directed to Form II of sertraline hydrochloride and novel methods for its preparation. According to the present invention, sertraline hydrochloride Form II may be produced directly form sertraline base or sertraline mandelate. It may also be produced from sertraline hydrochloride solvate and hydrate forms, and crystallized from new solvent systems. Pharmaceutical compositions containing sertraline hydrochloride Form II and methods of treatment using such pharmaceutical compositions are also disclosed.

Abstract: The present invention provides a process for the optical resolution of racemic tomoxetine under reaction conditions that improve reaction yields and optical purity. The invention also provides an epimerization process for the (S)-(+) enantiomer. The invention further provides the conversion of the enantiomer obtained from the optical resolution into atomoxetine or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides novel polyamine and amino thiol compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more chemoprotective polyamines or amino thiols formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.

Abstract: The present invention provides a drug delivery vehicle that can improve the pharmacokinetics of pharmacological agents. The invention relates to a multifunctional carrier capable of delivering a carried material such as a pharmacological agent or genetic material to a recipient. The multifunctional carrier includes a multifunctional core and a plurality of adduct molecules bonded thereto. The molecular carrier has surface functional groups which can be associated with a carried material. The carried material can be associated with the molecular carrier through covalent interactions or ionic interactions. The polyvalent core can be ethylene-diamine tetraacetic acid (EDTA) or succinic acid. The invention also relates to methods for producing and using such molecules.

Abstract: Embodiments of the present invention disclose a process for the co-production of bis(para-aminocyclohexyl) methane (PACM). Also disclosed are articles of manufacture made using PACM produced by methods of this invention. The methods of the present invention generally include a first mixture having methylene di-aniline (MDA) and a second aromatic amine. The first mixture has less than 15% polymeric MDA by weight and the second aromatic amine is present in an amount to render the first mixture a liquid. The first mixture is hydrogenated to produce a product mixture comprising PACM and at least one second non-aromatic amine.

Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

Abstract: Phenoxy amine compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Abstract: The present invention relates to an improved process for preparing enantiomerically pure 3-hydroxy-3-phenyl-propylamines on an industrial scale using asymmetrical hydrogenation as a key step and optionally a special sequence of subsequent steps, using a catalyst system consisting of rhodium and chiral 4-(dicyclohexylphosphino)-2-(diphenyl-phosphino-methyl)-N-methyl-aminocarbonyl-pyrrolidine.

Abstract: The present application describes modulators of chemokine receptors of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

Abstract: Process for the catalytic hydrogenation of a nitrite in the presence of an amine and a catalyst wherein the catalyst is a liquid-rinsed Raney-type catalyst contacted with a hydroxide prior to contacting the catalyst with the amine. The process results in higher selectivity in the formation of diamines from diniriles.

Abstract: An alkylation method comprises reacting a hydroxy aromatic compound with an alkyl alcohol in the presence of an alkylation catalyst comprising a metal oxide wherein the alkylation catalyst, has a surface area to volume ratio of about 950 to about 4,000 m2/m3, an aspect ratio of about 0.7 to about 1.0 or a combination of the foregoing.

Abstract: The present invention provides terphenyl guanidine compounds of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.